All In Biotech

Drug Trial Radar · NCT02452190

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

468

Actual

Start

Sep 28, 2015

Primary completion

Dec 4, 2017

Study completion Jan 31, 2018

Sponsor

Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
May 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.

Conditions

  • Asthma

Interventions

  • ReslizumabDrug

    Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of TreatmentTime frame: Day 1 to Week 52

Locations

226 sites in 21 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 13212

    Birmingham, Alabama

  • Teva Investigational Site 13241

    Flagstaff, Arizona

  • Teva Investigational Site 13194

    Glendale, Arkansas

  • Teva Investigational Site 13215

    Bakersfield, California

  • Teva Investigational Site 13181

    Canoga Park, California

  • Teva Investigational Site 13254

    Fresno, California

  • Teva Investigational Site 13216

    Huntington Beach, California

  • Teva Investigational Site 13247

    Long Beach, California

  • Teva Investigational Site 13205

    Napa, California

  • Teva Investigational Site 13764

    San Jose, California

  • Teva Investigational Site 13252

    Stockton, California

  • Teva Investigational Site 13251

    Walnut Creek, California

  • Teva Investigational Site 13229

    Denver, Colorado

  • Teva Investigational Site 13766

    Waterbury, Connecticut

  • Teva Investigational Site 13196

    Aventura, Florida

  • Teva Investigational Site 13256

    Fort Lauderdale, Florida

  • Teva Investigational Site 13203

    Kissimmee, Florida

  • Teva Investigational Site 13197

    Miami, Florida

  • Teva Investigational Site 13220

    Miami, Florida

  • Teva Investigational Site 13243

    Miami, Florida

  • Teva Investigational Site 13233

    New Port Richey, Florida

  • Teva Investigational Site 13201

    Orlando, Florida

  • Teva Investigational Site 13250

    Orlando, Florida

  • Teva Investigational Site 13246

    Pembroke Pines, Florida

  • Teva Investigational Site 13208

    Tallahassee, Florida

  • Teva Investigational Site 13255

    Tampa, Florida

  • Teva Investigational Site 13765

    Albany, Georgia

  • Teva Investigational Site 13249

    Buford, Georgia

  • Teva Investigational Site 13763

    Lawrenceville, Georgia

  • Teva Investigational Site 13230

    Chicago, Illinois

  • Teva Investigational Site 13211

    Normal, Illinois

  • Teva Investigational Site 13235

    Shiloh, Illinois

  • Teva Investigational Site 13202

    Michigan City, Indiana

  • Teva Investigational Site 13225

    Lenexa, Kansas

  • Teva Investigational Site 13222

    Owensboro, Kentucky

  • Teva Investigational Site 13191

    Lafayette, Louisiana

  • Teva Investigational Site 13200

    North Dartmouth, Massachusetts

  • Teva Investigational Site 13226

    Biloxi, Mississippi

  • Teva Investigational Site 13204

    St Louis, Missouri

  • Teva Investigational Site 13258

    Boys Town, Nebraska

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.